Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19

Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19

Objective: This study aimed to estimate the cost-effectiveness of nirmatrelvir/ritonavir (NMV/r) versus the standard of care (SoC) for patients with mild-to-moderate coronavirus disease 2019 (COVID-19) at high risk for progression to severe illness from the perspective of the Italian National Healt...

Full description

Saved in:
Bibliographic Details
Main Authors: Carolina Moreno, Andrea Aiello, Roberto Di Virgilio, Valentina Mazzotta, Andrea Antinori
Format: Article
Language:English
Published: AboutScience Srl 2025-07-01
Series:Global & Regional Health Technology Assessment
Subjects:
Cost-effectiveness analysis
Cost-utility analysis
COVID-19
Italy
nirmatrelvir/ritonavir
Online Access:https://journals.aboutscience.eu/index.php/grhta/article/view/3403
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items